Has the U.K. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 3.7x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 30 Jun 2026	UK£3.3b	UK£893.8m	-UK£153,955,485.95	18.5x	-21.4x	3.7x
Thu, 28 May 2026	UK£3.5b	UK£892.4m	-UK£149,333,645.70	19.3x	-23.4x	3.9x
Sat, 25 Apr 2026	UK£3.1b	UK£889.7m	UK£11.4m	11.9x	270.1x	3.5x
Mon, 23 Mar 2026	UK£3.1b	UK£875.5m	-UK£4,263,131.48	8.7x	-733.6x	3.6x
Wed, 18 Feb 2026	UK£3.7b	UK£876.1m	-UK£28,128,353.08	9.8x	-133.3x	4.3x
Fri, 16 Jan 2026	UK£3.6b	UK£876.1m	-UK£28,249,952.42	10.3x	-129.1x	4.2x
Sun, 14 Dec 2025	UK£3.2b	UK£896.9m	-UK£29,242,407.50	9.7x	-108.2x	3.5x
Tue, 11 Nov 2025	UK£3.1b	UK£886.5m	-UK£43,054,171.70	11.3x	-71.6x	3.5x
Thu, 09 Oct 2025	UK£3.3b	UK£878.8m	-UK£40,750,546.75	16x	-80.9x	3.8x
Sat, 06 Sep 2025	UK£3.5b	UK£856.9m	-UK£84,171,834.79	16.3x	-41.4x	4.1x
Mon, 04 Aug 2025	UK£3.1b	UK£855.0m	-UK£102,705,682.96	13x	-30.3x	3.6x
Wed, 02 Jul 2025	UK£2.6b	UK£854.1m	-UK£103,896,898.44	13x	-24.6x	3x
Fri, 30 May 2025	UK£2.5b	UK£879.1m	-UK£92,065,760.66	13.8x	-26.7x	2.8x
Sun, 27 Apr 2025	UK£2.1b	UK£876.5m	-UK£171,010,503.11	17.2x	-12.3x	2.4x
Tue, 25 Mar 2025	UK£2.4b	UK£844.1m	-UK£277,392,243.99	16.7x	-8.6x	2.8x
Thu, 20 Feb 2025	UK£2.7b	UK£841.7m	-UK£294,154,841.09	84.5x	-9x	3.2x
Sat, 18 Jan 2025	UK£2.7b	UK£842.7m	-UK£297,323,030.32	85.2x	-9.2x	3.2x
Mon, 16 Dec 2024	UK£2.6b	UK£841.7m	-UK£294,234,688.84	79.2x	-9x	3.1x
Wed, 13 Nov 2024	UK£2.8b	UK£840.7m	-UK£293,766,111.71	88x	-9.6x	3.3x
Fri, 11 Oct 2024	UK£2.9b	UK£840.2m	-UK£295,657,028.93	97.4x	-10x	3.5x
Sun, 08 Sep 2024	UK£2.7b	UK£830.5m	-UK£314,446,085.32	82.9x	-8.7x	3.3x
Tue, 06 Aug 2024	UK£2.6b	UK£838.2m	-UK£257,829,540.40	30.2x	-9.9x	3x
Thu, 04 Jul 2024	UK£2.5b	UK£835.6m	-UK£260,780,212.79	30.1x	-9.8x	3.1x
Sat, 01 Jun 2024	UK£3.0b	UK£836.3m	-UK£287,266,028.40	30.6x	-10.3x	3.6x
Mon, 29 Apr 2024	UK£3.1b	UK£895.9m	-UK£215,717,681.40	29.7x	-14.4x	3.5x
Wed, 27 Mar 2024	UK£3.1b	UK£903.1m	-UK£202,183,517.28	28.5x	-15.4x	3.5x
Fri, 23 Feb 2024	UK£3.2b	UK£913.3m	-UK£197,835,821.65	31.2x	-16.2x	3.5x
Sun, 21 Jan 2024	UK£6.4b	UK£1.3b	-UK£245,297,001.00	37.3x	-25.9x	5x
Tue, 19 Dec 2023	UK£6.1b	UK£1.3b	-UK£245,590,728.00	37x	-25x	4.8x
Thu, 16 Nov 2023	UK£6.5b	UK£1.3b	-UK£242,394,041.00	39.3x	-26.6x	5.1x
Sat, 14 Oct 2023	UK£6.6b	UK£1.3b	-UK£251,319,262.00	38.4x	-26.1x	5.1x
Mon, 11 Sep 2023	UK£6.5b	UK£1.3b	-UK£207,007,212.00	23.6x	-31.6x	5.1x
Wed, 09 Aug 2023	UK£6.8b	UK£1.3b	-UK£209,217,365.00	23.4x	-32.5x	5.4x
Fri, 07 Jul 2023	UK£6.7b	UK£1.3b	-UK£209,039,838.00	23.9x	-32x	5.3x


GB Market	0.17%
Healthcare	5.87%
Biotech	0.41%
Biotech	0.41%

Company	Last Price	7D	1Y	Valuation
OXB Oxford Biomedica	UK£6.28	5.0% +UK£36.3m	98.4%	PS4.5x
AVCT Avacta Group	UK£0.76	5.6% +UK£18.7m	145.2%	PS3150.3x
PRTC PureTech Health	UK£1.34	1.1% +UK£3.4m	7.5%	PS92.8x
APTA Aptamer Group	UK£0.0055	4.8% +UK£863.8k	34.1%	PS13.8x
GENF Genflow Biosciences	UK£0.022	7.1% +UK£849.6k	210.3%	PS21.8x

Announcement • Jun 24

Coiled Therapeutics plc Announces Appointment of Craig A. Tooman to Independent Non-Executive Director, Effective June 25, 2026

Coiled Therapeutics plc announced the appointment of Craig A. Tooman as an Independent Non-Executive Director with effect from June 25, 2026. Mr. Tooman most recently served as President, Chief Executive Officer and Board Director of Silence Therapeutics, the NASDAQ-listed siRNA company and brings over 30 years of international pharmaceutical and biotechnology leadership experience spanning clinical, operational, financial, M&A and capital markets disciplines, including more than 20 years as a public company CEO and CFO. In these executive roles and as a Board member, he directly participated in the raising of nearly USD 9 billion in capital. At Silence Therapeutics, he helped transform the business from an early-stage UK research enterprise mainly trading on AIM into a well-financed NASDAQ listed global development company with multiple assets in later-stage clinical trials, including a first-in-class treatment for polycythemia vera. Throughout his career, he has played leading roles building, financing and realising value in life-science companies, participating in the execution of numerous strategic transactions across the biotechnology sector. As President, CEO and Board Director of Aratana Therapeutics, he negotiated the company's USD 250 million merger with Elanco following Aratana Therapeutics' Bloomberg "IPO of the Year" award in 2013 and a record-setting three US regulatory approvals in a single year. As CFO of Enzon Pharmaceuticals, he coordinated the sale of its specialty pharmaceutical business to Sigma Tau for over USD 300 million, and at ILEX Oncology he led the USD 1.1 billion acquisition by Genzyme Corporation, including its integration. Earlier in his career, he held senior strategic and investor relations roles at Pharmacia, Pharmacia & Upjohn and The Upjohn Company in the US, Europe and Japan. Mr. Tooman also brings extensive board experience, having served on the Supervisory Board of CureVac N.V. from 2019 until its acquisition by BioNTech in 2025, where he chaired both the Compensation and Nomination/Governance Committees, and on the boards of Aratana Therapeutics, Verté Therapeutics, Ondine Biomedical, Insite Vision and Xanodyne Pharmaceuticals, chairing the Audit Committees of four of these companies. His deep oncology heritage, including building the most valuable oncology business in Texas (ILEX Oncology) during the period 2002-2005, for which he was awarded the first Entrepreneur in Residence (EIR) designation by the Cancer Prevention and Research Institute of Texas (CPRIT), aligns directly with Coiled Therapeutics' precision oncology focus and its lead candidate, AO-252. Craig Allen Tooman, aged 60, currently holds or has held the following directorships or partnerships in the past five years: Current: Stockbourne LLC. Past five years: Silence Therapeutics plc, Silence Therapeutics Inc, Silence Therapeutics (London) Limited, Silence Therapeutics GmbH, Innopeg Limited, CureVac N.V., Verté Therapeutics Inc., Ondine Biomedical Inc.

Announcement • Jun 22

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Solvonis Therapeutics plc announced positive pharmacokinetic (PK) data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is Solvonis' proprietary esketamine oral thin-film (OTF) formulation being developed for moderate-to-severe Alcohol Use Disorder (AUD) in the United States. It is designed for supervised, clinic-administered sublingual-buccal dosing. The programme also incorporates a structured alcohol education component, intended for future remote digital access by patients. The programme is being advanced under a planned U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway referencing the FDA-approved intranasal esketamine product, Spravato®. The nonclinical study was designed to assess whether the intended combined sublingual-buccal administration of SVN-002 could generate systemic esketamine exposure supportive of a scientific bridge to the approved intranasal esketamine reference product. At the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm, providing important translational support for the planned scientific bridge. At the December 2024 Type B pre-IND meeting held with the FDA by Awakn Life Sciences, prior to the asset's acquisition by Solvonis, FDA identified systemic exposure to esketamine and relevant metabolite exposure as key considerations for the initial Investigational New Drug (IND) package. Solvonis believes these newly generated data provide important translational support in relation to the FDA-identified exposure considerations and strengthen the planned initial IND package for SVN-002. Following these positive results, Solvonis will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial IND submission. Subject to FDA feedback and successful completion of this targeted toxicology package, Solvonis plans to submit an IND to support the initiation of a Phase 2b clinical trial of SVN-002 in patients with moderate-to-severe AUD in the United States. AUD represents a major and underserved U.S. market opportunity characterised by limited pharmacological innovation. According to the 2024 U.S. National Survey on Drug Use and Health, approximately 27,900,000 people aged 12 and older in the U.S. had Alcohol Use Disorder in the past year. Solvonis estimates that approximately 15,000,000 U.S. adults fall within the programme's target moderate-to-severe AUD population. Spravato® provides a relevant commercial reference point for supervised, clinic-administered esketamine treatment models. Johnson & Johnson reported worldwide Spravato® sales of approximately USD 1,700 million in 2025 for depression-related indications. Solvonis estimates that SVN-002's target U.S. moderate-to-severe AUD population is approximately five times larger than the estimated U.S. treatment-resistant depression comparator population of approximately 2,800,000 people. The planned 505(b)(2) pathway is central to the capital efficiency of the SVN-002 development strategy. A successful 505(b)(2) route may allow Solvonis to rely, in part, on the FDA's prior findings of safety and/or effectiveness for the approved intranasal esketamine reference product, provided a suitable scientific bridge is established. Solvonis intends to build the SVN-002 package using existing third-party preclinical data, in-licensed Phase 1 clinical data, and targeted SVN-002 bridging and toxicology studies, rather than duplicating a full conventional de novo development package. The Company believes this approach has the potential to reduce development expenditure and support a more capital-efficient route towards Phase 2b. The pharmacokinetic profile observed in this study is very encouraging. Combined sublingual-buccal administration produced rapid systemic exposure to parent esketamine and supports the core rationale for SVN-002 as a transmucosal thin-film product. These results provide important translational evidence for the planned U.S. regulatory pathway and support SVN-002's continued development as a supervised, clinic-administered treatment candidate for AUD.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

PRTC: London-Only Listing Will Refocus Trading And Unlock Future Upside

Coiled Therapeutics plc Announces Appointment of Craig A. Tooman to Independent Non-Executive Director, Effective June 25, 2026

OXB: Fast-Track Viral Vector Services Will Support Higher Quality Business Perception

New minor risk - Share price stability

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Investor sentiment improves as stock rises 18%

Hemogenyx Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2026

Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026

New major risk - Revenue and earnings growth

ProBiotix Health Plc, Annual General Meeting, Jun 23, 2026

OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026

New minor risk - Share price stability

New major risk - Shareholder dilution